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Abstract We evaluated the eects of 5-fluorouracil
(5FU) and leucovorin (LV) on thymidylate synthase
(TS) in normal rapidly dividing tissues, which may
contribute to toxic side-eects of treatment with 5FU
and LV. TS levels were determined in biopsies of human
liver and colon mucosa and murine bone marrow, liver
and intestinal mucosa at several time points after ad-
ministration of therapeutic doses of 5FU or LV/5FU. In
murine liver, after treatment with 100 mg/kg 5FU, TS
inhibition was significantly higher than after LV/5FU
administration (P<0.001). A similar trend was observed
in human liver tissue. Murine intestinal mucosa had TS
levels below the limit of detection after 5FU or LV/5FU
treatment. In human colon mucosa samples, adminis-
tration of 500 mg/m2 5FU resulted in a large extent of
TS inhibition but the small number of samples did not
allow a time- or 5FU-LV/5FU-related evaluation. TS
activity in murine bone marrow cells was strongly in-
hibited to 10% of the control value during 48 h. LV/
5FU administration resulted in a slightly higher inhibi-
tion. No human bone marrow was available to measure
TS levels. Both in mice and humans the most pro-
nounced TS inhibition occurred in the tissue that was
involved in dose-limiting toxicity. Therefore it is very
likely that TS inhibition in normal tissues contributes to
the toxic side-eects of 5FU treatment.
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Introduction
Combination chemotherapy of 5-fluorouracil (5FU) and
leucovorin (LV) is mainly used for the treatment of co-
lon cancer, but has also been applied for breast and head
and neck cancer (Peters and van Groeningen 1991). In
this combination 5FU is the active cytotoxic agent. The
5FU nucleotides 5-fluorouridine 5¢-triphosphate
(FUTP) and 5-fluoro-2¢-deoxyuridine 5¢-triphosphate
(FdUTP) can be misincorporated into RNA and DNA
respectively. A third metabolite, 5-fluoro-2¢-deoxyuri-
dine 5¢-monophosphate (FdUMP) is a potent inhibitor
of the enzyme thymidylate synthase (TS, EC 2.1.1.45;
5,10-methylenetetrahydrofolate:dUMP C-methyltrans-
ferase), an essential enzyme in the synthesis of DNA.
The inhibition of TS by FdUMP can be enhanced and
prolonged by the LV metabolite 5,10-methylene-
tetrahydrofolate (5,10-CH2-H4-folate). A stable ternary
complex is formed consisting of TS, FdUMP and CH2-
H4-folate (Danenberg 1977). This biochemical eect
forms the background for the coadministration of LV
with 5FU. Naturally occurring low 5,10-CH2-H4-folate
levels in tissues, which are limiting for inhibition of TS,
can be elevated by LV administration. Administration of
LV/5FU to patients has been shown to result in a better
inhibition of TS than that produced by 5FU alone
(Swain et al. 1989; Peters et al. 1994). The increased TS
inhibition observed after LV/5FU resulted in a better
antitumour eect, compared to the eects of single-
agent 5FU (Swain et al. 1989). These observations reflect
the importance of TS inhibition in tumours with regard
to antiproliferative eects.
The most frequently seen dose-limiting toxic side-
eects of 5FU aremyleosuppression after bolus injections
and gastrointestinal toxicity after continuous infusion of
5FU (Peters and van Groeningen 1991; Leichman 1994).
Coadministration of LV and 5FU did not only improve
the antitumour activity of 5FU, as has been shown in
both murine and human colon tumours, but also in-
creased the gastrointestinal toxicity compared with bo-
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lus 5FU treatment in both species (Nadal et al. 1988;
Piedbois et al. 1992). It has not been completely eluci-
dated which of the biochemical mechanisms of action of
5FU is involved in toxic side-eects in normal tissues.
For gastrointestinal mucosa, incorporation into the
RNA was postulated to be an important mechanism in
mice (Houghton et al. 1979; Martin et al. 1982), but not
much has been written about the mechanism for bone
marrow cells and liver tissue. It has been shown that
delayed uridine administration reduces myeloid toxicity
(Nadal et al. 1989; van Groeningen et al. 1989, 1993).
This observation indicates the type of RNA eects that
are related to toxicity, since uridine reduced 5FU in-
corporation into RNA, but did not aect TS inhibition
(Peters et al. 1988; Nord et al. 1992).
Little is known about TS activity and 5FU-induced
TS inhibition in normal human tissues. One may
speculate that TS levels are relatively high in rapidly
dividing and DNA-synthesising tissues, such as the
gastrointestinal mucosa and bone marrow. Is TS in-
hibited in these tissues after 5FU administration?
Furthermore is there a relation between TS inhibition
and the toxic side-eects of 5FU administration that
occur in these tissues?
We studied the eect of i.p. 5FU administration on
the inhibition of TS in normal murine bone marrow,
intestinal mucosa and liver tissues. The murine liver
tissue was included in this study because of the com-
parison with human liver that could be obtained from
patients with liver metastases of colon cancer. A study of
Harrison et al. (1978) has shown that toxicity due to
5FU in mice is highly similar to that in humans. The
eects of coadministration of LV with 5FU on TS were
primarily studied in mice. We compared the preclinical
results with TS inhibition measured in liver and normal
colon mucosa of patients, who had received a bolus in-
jection of 5FU or LV infusion with a midway bolus
injection of 5FU before surgery. The present study,
performed in normal tissues of mice and humans, pro-
vides an insight into the contribution of TS inhibition to
the toxic side-eects of 5FU.
Materials and methods
Materials
5FU was obtained from ABIC (Netanya, Israel) and LV was
provided by Wyett-Lederle (Amsterdam, The Netherlands) and the
pharmacy department of the Free University Hospital (Amster-
dam, the Netherlands). [6-3H]FdUMP (specific activity 20 Ci/
mmol) was purchased from Moravek Biochemicals Inc. (Brea,
Calif., USA) and [5-3H]dUMP (specific activity 10.9 Ci/mmol)
from Amersham International (Buckinghamshire, England). All
other chemicals were of analytical grade, and were commercially
available.
Mice
Female Balb/c mice (age 8–10 weeks, about 20 g) (Harlan/Olac;
C.P.B., Zeist, The Netherlands) received a single i.p. bolus injection
of 100 mg/kg 5FU. This is the maximal tolerated dose for weekly
i.p. injections (Peters et al. 1987). LV was given as an i.p. bolus
injection 1 h before and together with 5FU in two doses of 50 mg/
kg (total dose LV 100 mg/kg). This schedule was derived from the
experiments of Nadal et al. (1988). At this dose the weight loss of
mice amounted to 5%–15% as a result of gastrointestinal toxicity,
while blood cells decreased to 40%. No liver toxicity was apparent.
Delivery by i.p. bolus in small animals such as rats and mice results
in pharmacokinetic behaviour similar to that following systemic i.v.
bolus treatment in man (De Bruijn et al. 1986; Peters et al. 1993),
such as a comparable half-life of 10–15 min.
Liver tissue, intestinal mucosa and bone marrow cells of the
mice were removed 3, 24 and 48 h after treatment and immediately
frozen in liquid nitrogen. Samples from untreated mice served as
controls.
Patients
Patients in this study (Table 1) all underwent surgery for thera-
peutic purposes, i.e. implantation of a Port-a-Cath to be used for
subsequent hepatic arterial infusions with 5FU. Informed consent
was obtained from all patients before surgery and drug adminis-
tration. Control liver samples were obtained from 8 patients with a
known malignant disease, namely colon cancer without liver me-
tastases. 5FU or LV/5FU samples (colon and/or liver tissue) were
from patients who all had histologically proven colorectal cancer.
These patients (36) received a single dose of 5FU at 500 mg/m2 or
(29 patients) were given LV administered as a 2-h infusion, with a
bolus injection of 5FU at 500 mg/m2 in the middle of the infusion.
Three doses of LV were used: 25 mg/m2 or 500 mg/m2 racemic DL-
LV or 250 mg/m2 purified L-LV, which is believed to be the more
active of the stereoisomers. These chemotherapeutic agents were
given as a single test dose before surgery in order to examine in-
hibition of TS in surgical samples. Biopsy specimens were taken
between 1 h and 48 h after treatment and immediately frozen in
liquid nitrogen.
Thymidylate synthase assays on tissues
TS inhibition was evaluated with two assays, which provided dif-
ferent information. The ligand-binding assay gives an estimate of
the amount of (free) TS protein. The assay with [6-3H]FdUMP
determined the free binding sites for FdUMP. Tissue homogenate
was incubated with [6-3H]FdUMP and the cofactor 5,10-CH2-H4-
folate at 37°C. After 1 h, free [6-3H]FdUMP was removed by a
charcoal wash and [6-3H]FdUMP bound to TS was counted. The
other assay, the 3H-release assay, gives information about the
catalytic activity of the enzyme. One binding site, as measured in
the ligand-binding assay, can serve for one or more catalytic con-
versions. We used [5-3H]dUMP to measured the catalytic activity
of the enzyme in converting dUMP into dTMP. Two substrate
Table 1 Data on patient characteristics and sample numbers. The
number of patients in each drug administration group and the
number of tissue samples obtained from the whole patient group
are summarized. 5FU 5-fluorouracil, LV leucovorin. Subscripts
(DL-LV25 etc.) indicate the doses used (mg/m
2)
Number (male/female) 73 (37/36)
Median age (years) 55 (34–78)
Control 8 patients
5FU 36 patients
LV/5FU (DL-LV25; DL-LV500; L-LV250) 29 (11; 10; 8) patients
Colon mucosa only 5 patients
Liver only 57 patients
Colon mucosa and liver 11 patients
Total colon mucosa 16 samples
Total liver 68 samples
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concentrations of dUMP were used in the catalytic activity assay:
1 lM, which is around the Km, and 10 lM, a saturating substrate
concentration. Tissue homogenate was incubated with [5-3H]dUMP
and the cofactor 5,10-CH2-H4-folate at 37°C. After 30 min
[5-3H]dUMP bound to TS and free [5-3H]dUMP were precipitated
by an acid charcoal wash. The amount of [3H]H2O released during
the reaction was measured in the supernatant. Details of the assays
have been published elsewhere (van der Wilt et al. 1992; Peters et al.
1991, 1994).
The control values of murine tissues were determined by mea-
suring TS in samples of untreated mice. The Balb/c mice that we
used are an inbred strain and genetically nearly identical, so vari-
ations in TS are small.
We used two methods to determine control values in the human
tissues. First, controls for the patient’s material were obtained by a
dissociation procedure performed on a part of each 5FU or LV/
5FU sample, since it was not possible to receive control tissue from
the same patient before 5FU injection. The dissociation procedure
removed all FdUMP bound to TS in the presence of a high con-
centration dUMP. The free FdUMP was absorbed with neutral
charcoal. Details of the procedure have been described previously
(van der Wilt et al. 1992). Second, we obtained control liver sam-
ples from untreated patients. These samples underwent the same
procedure as the 5FU and LV/5FU samples: one part was used for
the dissociation procedure followed by TS assays, the other part
was used for direct measurement of TS. This allowed us to check
the eects of the dissociation procedure in liver samples. FdUMP
binding measured after dissociation is referred to as TS-tot, while
directly measured FdUMP binding is called TS-free. Analogous TS
activity measured after dissociation is called TS-total and directly
measured activity is referred to as residual TS activity. Further-
more, we examined whether addition of 0.01 lM FdUMP in the
catalytic activity assay would lead to the same extent of TS inhi-
bition in directly measured samples and samples measured after
dissociation. The colon mucosa samples obtained from patients
treated with 5FU or LV/5FU were handled like the liver samples.
Control values for colon mucosa of untreated patients were derived
from previously published experiments (Peters et al. 1991).
We also attempted to measure TS levels in human lymphocytes
as an indication of bone marrow TS. Up to 9 ´ 107 cells were
collected from healthy volunteers, but even with this high number
of cells per assay, TS levels were below the detection limit.
Statistics
The results were evaluated using Student’s t-test for paired and
unpaired data.
Results
Mice
The i.p. 5FU or LV/5FU treatment aected TS in nor-
mal tissues of the mice. TS inhibition in murine liver was
evaluated both with the ligand-binding assay and the
catalytic activity assay and is summarized in Table 2.
Both assays showed that the LV/5FU treatment caused
no inhibition of TS in the liver, while treatment with
5FU as a single agent caused a significant inhibition of
TS activity at 24 h and 48 h. The ratio calculated from
separate values for catalytic activity, measured at 1 lM
and 10 lM dUMP, was 2.0  0.03 for the control and is
indicative of a dierence in the enzyme kinetic proper-
ties. A significant decrease of this ratio was observed
48 h after 5FU treatment (1.7  0.1, P < 0.001), while
the ratio increased significantly after LV/5FU adminis-
tration (2.2  0.1, P < 0.05). LV/5FU had a slight
inhibitory eect at 1 lM dUMP, while single-agent 5FU
exerted its major eect at 10 lM. This could be, for
example, a change in Ki for FdUMP, which was 0.5 nM
in control liver.
The control values for TS in intestinal mucosa were
about 1.5-fold higher than in liver (6.6 compared to
4.3 pmol/g wet weight for FdUMP binding and 130
compared to 80 pmol h)1mg protein)1 for catalytic ac-
tivity respectively). After treatment, no activity of TS
could be observed in mucosa; all values at 3, 24 and 48 h
were below the detection limit of both TS assays.
FdUMP binding lower than 4 fmol/mg protein and
catalytic activity lower than 10 pmol h)1 mg protein)1
could not be measured reliably in murine mucosa.
FdUMP binding in bone marrow could be measured
in pooled control samples and was 1471  293 fmol/mg
protein; the catalytic activity of TS at 1 lM and 10 lM
was 1081 pmol h)1 mg protein)1 and 4622 pmol h)1 mg
protein)1 respectively. After treatment, TS inhibition
was only evaluable with the 3H-release assay at 1 lM
dUMP (Fig. 1). This assay allowed the detection of a
high degree of TS inhibition (above 90%) at 3 h and
48 h. LV/5FU treatment resulted in a slightly higher
Table 2 FdUMP binding and thymidylate synthase (TS) catalytic activity in murine liver. This was measured at three time points after
treatment of the mice with 5FU (100 mg/kg) or LV (100 mg/kg) and 5FU and compared to control murine liver tissue. Values are means
 SD, n = 3–6; protein content of liver: 99  14 mg protein/g wet weight
FdUMP binding
TS catalytic activity
(pmol/h)1 mg protein)1)
(pmol/g protein) At 1 lM dUMP At 10 lM dUMP
Time (h) 5FU LV/5FU 5FU LV/5FU 5FU LV/5FU
Control 43  7 43  7 20  16 80  16 149  44 152  44
3 34  4 37  5 74  3 74  5 149  17 148  12
24 27  3* 40  5 50  3 68  7 90  25 142  21**
48 31  2* 37  2 39  3 65  2 65  7 142  4**
* Significantly dierent from control (P < 0.05, Student’s t-test unpaired data)
** Significantly dierent from 5FU treatment 24 h (P < 0.02) and 48 h (P < 0.001, Student’s t-test unpaired data)
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inhibition of TS activity at the dierent assay times than
did 5FU treatment, but dierences were only significant
at 3 h (P<0.001). The unexpected higher activity of TS
at 24 h, compared to 48 h, was found for both treat-
ments.
Patients
The dissociation procedure was intended to provide an
internal control for all liver samples obtained after 5FU
or LV/5FU administration. However, the TS catalytic
activity measured after dissociation (TS-total) was lower
than the residual TS activity in 31 of 53 liver samples.
This indicated a loss of TS activity during the 3-h dis-
sociation procedure. Control human liver samples were
subsequently used to examine the eects of the dissoci-
ation procedure. FdUMP binding measured in control
samples from untreated patients was not influenced by
the dissociation procedure; values were about 70 pmol/
mg protein (Table 3). However, these values are much
higher than the TS-tot measured after 5FU and LV/
5FU: 15.3 pmol/mg protein (Table 4). This indicated
that 5FU with or without LV influenced TS-tot levels in
the liver. TS catalytic activity, measured directly or after
dissociation, showed that the dissociation procedure
clearly diminished the activity of TS and also the Ki of
FdUMP seemed to be aected (Table 3).
We could evaluate FdUMP binding in 47 of 60 liver
samples obtained after 5FU or LV/5FU administration.
TS-free values were lower than TS-tot values 2 h and
48 h after 5FU or LV/5FU, indicating inhibition of TS,
but TS-free was comparable to TS-tot 24 h after 5FU.
Fig. 1 Comparison of residual thymidylate synthase catalytic activity
(at 1 lM dUMP) after i.p. treatment with 100 mg/kg 5-fluorouracil
(5FU; d) or 100 mg/kg leucovorin and 100 mg/kg 5FU (.) in murine
bone marrow cells. Values are means  SD, n = 3–5, protein
content about 18 lg protein/106 cells
Table 3 FdUMP binding and thymidylate synthase catalytic activity in control liver of patients. The values are means  SD of 6–8
samples. Ki values were calculated from each separate sample
TS parameters Direct measurement Measurement after dissociation
FdUMP binding (fmol/mg protein) 73.8  20.8 70.0  33.9
TS catalytic activity (pmol/h)1 mg protein)1) at:
1 lM dUMP 2.92  1.87 1.14  0.89*
1 lM dUMP + 10 nM FdUMP 1.03  0.98 0.62  0.54**
10 lM dUMP 13.4  12.7 7.0  4.3***
10 lM dUMP + 10 nM FdUMP 8.7  7.5 7.6  4.2
Ki FdUMP (nM) 2.7  2.0 10.7  8.3
*–***Values significantly lower after dissociation (*P = 0.029, **P = 0.010 and ***P = 0.048, t-test for paired data)
Table 4 FdUMP binding to thymidylate synthase (TS) in human
liver after 5FU or LV/5FU administration. The values of TS-free
and TS-tot are means of evaluable samples  SD. FdUMP bind-
ing to TS-tot of 12 patients was below the detection limit and for 2
patients TS-tot was extremely high (88 and 1071 fmol/mg protein);
these were considered not evaluable and were not included in this
table. Protein content liver: 96  21 mg protein/g wet weight. e/n
number of evaluable samples compared to the total number of
samples
Time (h) Thymidylate synthase (fmol/mg protein)
Scheduled Actual Drug e/n TS-free TS-tot
Control 8/8 73.8 20.8
2 1.25–5.08 5FU 3/8 7.1  6.8*1 17.7 3.9
24 19.00–26.25 5FU 7/9 18.8  18.6 19.4 14.6
48 41.75–67.50 5FU 12/16 8.7  7.1*2 15.9 11.0
48 39.00–51.00 LV/5FU 25/27 11.3  5.8*3 14.0 9.2
40.08–48.80 DL-LV500/5FU 6/8 13.6  3.9 16.1 6.7
39.00–51.00 L-LV250/5FU 8/8 13.4  6.7 17.3 9.6
41.30–50.00 DL-LV25/5FU 11/11 8.5  5.3 10.6 9.6
Summary 1.25–50.00 5FU and LV/5FU 47/60 11.5  9.4 15.3 10.3*4
*1–*4Statistics: TS-free is lower than TS-tot: *1P = 0.04; *2P = 0.05; *3P = 0.02, paired t-test. TS-tot of 5FU and LV/5FU samples is
lower than TS-tot of control (*4P = 2 ´ 10)5, unpaired t-test)
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When measured after 48 h, 5FU samples had TS-free
values that were comparable to those of LV/5FU sam-
ples and also their relative inhibition, calculated by TS-
free/TS-tot, was comparable. So LV did not enhance
5FU-induced TS inhibition in liver tissue.
Figure 2a shows the residual TS catalytic activity in
liver samples at about 2, 24 and 48 h after 5FU injection.
Figure 2b shows a comparison of the activity at 48 h after
injection of 5FU (500 mg/m2) and infusion of dierent
doses of LV. We considered inhibition of TS activity
based on the ratio TS-residual/TS-total not evaluable in
these samples, because it is probable that, as in control
samples, dissociation reduced the TS-total activity (not
shown) by about 50%. Therefore we used the directly
measured activity of Table 3 as a reference TS-total; TS-
residual 48 h after 5FU and LV/5FU injection was higher
than this control, mainly because of the values of DL-
LV500 and L-LV250. At the other assay times TS-residual
was not significantly dierent from the control.
The enzyme assays in colon mucosa were not per-
turbed by the dissociation procedure. The total FdUMP
binding to TS (TS-tot) in human colon mucosa could
only be evaluated in 12 of the 17 biopsies (excluding
controls) and varied in these samples from 11.3 to
192 fmol/mg protein (Table 5). These TS-tot values did
not dier significantly from the controls, and both
groups showed a large variation. The remaining 4
samples had FdUMP binding below the detection limit
of the assay. The number of free sites for FdUMP
binding to TS after administration of 5FU or LV/5FU,
represented by TS-free, were all lower than the corre-
sponding TS-tot values. This indicated that FdUMP
binding sites were blocked and TS was inhibited in colon
mucosa.
TS catalytic activity (Fig. 3) could be evaluated in 15
of the 16 mucosa samples (excluding controls) of treated
patients. The TS-total value of these samples was sig-
nificantly higher than TS-total of the controls (28.4
 20.4 compared to 13.9  10.7). Inhibition of TS
catalytic activity after 5FU or LV/5FU was observed in
11 out of 15 samples. An elevation of TS-total activity
was observed 48 h after administration. The small
number of colon mucosa samples and the large variation
allowed no further time-dependent or treatment-related
evaluation.
Table 5 FdUMP binding to thymidylate synthase (TS) in human
colon mucosa after 5FU or LV/5FU administration. The values of
TS-free and TS-tot are means of evaluable samples  SD. FdUMP
binding to TS-tot of 4 patients (excluding controls) was below the
detection limit; these were considered not evaluable. Protein con-
tent: 42  10 mg protein/g wet weight. e/n number of available
samples compared to the total number of samples. Control values
from Peters et al. (1991)
Time (h) Thymidylate synthase (fmol/mg protein)
Scheduled Actual Drug e/n TS-free TS-tot
Control – 7/10 62.7  31.4
2 0.92–4.17 5FU 4/6 7.7  6.2* 21.1  7.3***
24 22.75 5FU 1/1 0 192.0
48 49.25; 67.50 5FU 2/2 17.8; 0 59.0; 20.9
48 43.80–50.30 LV/5FUa 5/8 20.2  13.5** 66.9  42.6
Summary 5FU and LV/5FU 12/17 57.6  54.5
a Specification LV dose per sample: 500 mg/m2 DL-LV (1); 250 mg/m2 L-LV (1); 25 mg/m2 DL-LV (3). **Statistics: TS-free is lower than
TS-tot: *P = 0.05; **P = 0.02, paired t-test. TS-tot 2 h after 5FU is lower than other TS-tot values ***P = 0.03, unpaired t-test
Fig. 2a, bResidual thymidylate synthase (TS) catalytic activity at 1 lM
dUMP in biopsy specimens of human liver. Patients received a single
dose of 500 mg/m2 5FU (a) or 500 mg/m2 DL-leucovorin (d,l-LV),
250 mg/m2 L-leucovorin (l-LV) or 25 mg/m2 DL-leucovorin in
combination with 500 mg/m2 5FU (b). Biopsy specimens were
obtained at the times indicated at the bottom of the figure. For time
0 h, the control value from Table 4 has been used. Statistics: residual
TS activity 48 h after drug administration is significantly higher than
the control (P = 0.05); specified per drug: 5FU 48,P = 0.12; 500 mg/
m2 DL-leucovorin +5FU, P = 0.013; 250 mg/m2 L-leucovor-
in +5FU, P = 0.054; 25 mg/m2 DL-leucovorin +5FU, P = 0.11
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Discussion
TS was inhibited in normal tissues after 5FU adminis-
tration, but the extent of inhibition varied with the tis-
sue. The most pronounced TS inhibition in mice was
observed in the intestinal mucosa, while there was a
tendency for higher TS inhibition in human colon tissue
than in human liver tissue, when calculated TS-free/TS-
tot values were used as markers for TS inhibition
(Tables 4 and 5). A large degree of TS inhibition in bone
marrow cells after 5FU administration was observed for
mice. This eect appeared to be very similar to that
observed for rats (van der Wilt et al. 1995). In murine
liver and in about 50% of the human liver samples, TS
inhibition was maintained for 48 h after 5FU.
When we added LV to the treatment schedule we
expected to enhance the 5FU-mediated TS inhibition.
This could not be evaluated in murine intestinal mucosa
with the TS assays because single-agent 5FU already
caused complete inhibition of the enzyme. Inhibition of
TS activity in the bone marrow cells after LV/5FU
treatment of the mice was not very dierent from that
observed after 5FU treatment. It was remarkable that,
in the livers of these animals, no inhibition of TS was
observed after LV/5FU treatment.
We observed a similar trend in human livers. Samples
of patients obtained 48 h after LV/5FU usually had
higher TS-free values (FdUMP binding to TS) than
samples obtained 48 h after 5FU. Concentrations of
natural folates measured in the liver were higher than
those in other tissues (Steinberg et al. 1979). Further-
more it is likely that mice have even higher folate levels
in their liver, because of their folate-rich diet. Conse-
quently addition of LV to the 5FU administered is un-
likely to increase TS inhibition in normal liver.
Dierences of TS inhibition in human colon mucosa
after 5FU or LV/5FU administration could not be
evaluated, because of the small number of samples.
The contribution of TS inhibition in normal tissues
to 5FU-mediated toxicity is dicult to assess. Gener-
ally, a pronounced TS inhibition was observed in those
normal tissues that were involved in the dose-limiting
toxicity of 5FU administration. Severe inhibition of TS
activity was observed in the intestinal mucosa and bone
marrow of treated mice. This corresponded to gastro-
intestinal toxicity, which has been described for i.p. in-
jection of 5FU (Bagrij et al. 1993), and to the myeloid
toxicity described by Nadal et al. (1989). Besides the
eects on TS, the biochemical eect of 5FU adminis-
tration on RNA should be taken into consideration,
since it has been shown that this may play a role in
gastrointestinal toxicity in mice (Houghton et al. 1979).
Bagrij et al. (1993) showed that, in mice, uridine could
partially reverse gastrointestinal toxicity. It is believed
that uridine metabolites compete with FUTP for in-
corporation into RNA. Myeloid toxicity in mice and
man could also be reduced by delayed uridine admin-
istration (Peters et al. 1988; van Groeningen et al. 1989,
1993). TS inhibition and FUTP incorporation into
RNA occur in both normal and rapidly dividing tissues
aected by the toxic side-eects of 5FU. From this
study it can not be concluded which contributes most to
the toxic side-eects.
TS inhibition in liver tissue seemed to be of minor
importance, since 5FU does not cause toxic side-eects
in the liver. However, there are some remarkable fea-
tures of TS inhibition in liver tissue that might explain
why no toxic side-eects occur. First, the extent of TS
inhibition, evaluated by FdUMP binding assay, was less
than in mucosa, for example. Second, TS inhibition was
not enhanced by co-administration of LV, indicating
that 5,10-CH2-H4-folate was not limiting for TS inhibi-
tion in this tissue. Imbalance of the folate homeostasis in
the liver, caused by LV administration, induced a reverse
eect on TS inhibition. Third, residual TS activity 48 h
after 5FU administration was higher than TS activity in
the control liver. A similar increase of TS-total was
observed in rat liver after FU administration (van der
Wilt et al. 1995).
The increase of TS activity after 48 h was also ob-
served in human colon mucosa. It appears to be a gen-
eral mechanism occurring both in vitro and in vivo as a
response to 5FU exposure and was first described by
Chu et al. (1991). The elevation of TS activity might be a
defence mechanism of cells and tissues against 5FU
toxicity.
The decrease in TS activity, observed after the dis-
sociation procedure, was specific for liver tissue. Pre-
vious tests in colon tumours from mice and men did not
reveal such eects. The presence of many proteases in
liver tissue might aect the stability of TS during the
incubation for 3 h at 30oC. Also the Ki for FdUMP was
Fig. 3 Inhibition of thymidylate synthase (TS) catalytic activity at
1 lM dUMP in human colon mucosa, obtained from patients who
received a single dose of 500 mg/m2 5-fluorouracil (5FU) or 500 mg/
m2 leucovorin (LV) and 500 mg/m2 5FU. The interval between
administration of the drug(s) and surgical removal of the tissue is
indicated at the bottom of the figure. White bars TS-residual, black
bars the corresponding TS-total from the same patients. No bar means
that the activity has been measured, but was below the detection limit
of the assay. At 0 h, data from Peters et al. (1991) were used. This bar
represents the mean of TS catalytic activity in colon mucosa of 10
untreated patients. Statistics: TS-total activity 48 h after drug
administration is significantly higher than TS activity of the control
(P = 0.006, unpaired t-test)
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altered, so considerable changes of the protein were in-
duced by this procedure.
Parallel to this study in normal tissues we measured
TS inhibition in murine and human colon tumours (van
der Wilt et al. 1992; Peters et al. 1994). Although TS
levels are higher in tumour tissue, the extent and, what is
more important, the retention of the inhibition in normal
tissues appeared to be less than in tumours obtained
from the same animals or the same patients. This implies
that, in tumour tissue, a stronger cytotoxic eect of 5FU,
measured by TS inhibition, occurs than in normal tis-
sues. So, despite toxic side-eects, 5FU treatment seems
to be selective for tumour tissue. This study shows that,
in normal tissues, especially bone marrow and intestinal/
colon mucosa, pronounced 5FU-mediated TS inhibition
could be measured. The same tissues are known to be
involved in toxic side-eects of 5FU. Toxicity is proba-
bly not only caused by 5FU-related eects on RNA but
may also be mediated by TS inhibition.
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